metformin has been researched along with Impaired Glucose Tolerance in 197 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 9.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 9.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 9.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Transplantation and Diabetes (Transdiab) is a single-centre, unblinded, pilot randomised controlled trial assessing the feasibility, tolerability and efficacy of metformin after renal transplantation in patients with impaired glucose tolerance (IGT)." | 9.30 | Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. ( Alnasrallah, B; Chan, LW; Goh, TL; Manley, P; Pilmore, H, 2019) |
| " The RISE Pediatric Medication Study compared two approaches-glargine followed by metformin and metformin alone-in preserving or improving β-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal." | 9.27 | Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. ( , 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 9.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 9.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "The Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke trial (MAAS trial) is a phase II, multicenter, randomized, controlled, open-label trial with blinded outcome assessment." | 9.20 | Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. ( Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA, 2015) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 80 patients with isolated impaired glucose tolerance and normal plasma lipids who complied with lifestyle modifications and received chronic fenofibrate treatment." | 9.17 | Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 43 patients with isolated impaired glucose tolerance and normal plasma lipids who had been treated for at least 6 months with micronized fenofibrate (200 mg daily)." | 9.17 | Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 9.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 9.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 9.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 9.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "Metformin attenuates hyperglycemia and increases muscle protein synthesis in severely burned patients, thereby indicating a metabolic link between hyperglycemia and muscle loss following severe injury." | 9.11 | Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. ( Gore, DC; Herndon, DN; Sanford, A; Wolf, SE; Wolfe, RR, 2005) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 9.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 9.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "To evaluate the effect of metformin on glucose metabolism, insulin sensitivity and rate of conversion diabetes in people with impaired glucose tolerance (IGT)." | 9.09 | Effect of metformin on patients with impaired glucose tolerance. ( Deng, XX; Li, CL; Lu, JM; Pan, CY; Wang, HY; Wang, HZ; Wang, JH; Xia, FC; Zhu, Y, 1999) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 9.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "To assess the effect of metformin on insulin sensitivity, glucose tolerance and components of the metabolic syndrome in patients with impaired glucose tolerance (IGT)." | 9.09 | Metabolic effects of metformin in patients with impaired glucose tolerance. ( Eriksson, JG; Forsén, B; Groop, L; Gullström, M; Häggblom, M; Lehtovirta, M; Taskinen, MR, 2001) |
| "Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied." | 8.12 | Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome. ( Chernikova, A; Dmitriev, A; Ermolenko, E; Galagudza, M; Gladyshev, N; Karonova, T; Kotyleva, M; Lavrenova, N; Minasian, S; Simanenkova, A; Suvorov, A; Timkina, N; Voropaeva, L, 2022) |
| "Although the beneficial effects of metformin (MET) and genistein in ameliorating inflammation have been elucidated, their combined impacts on skeletal muscle inflammation have not been clearly understood." | 8.02 | Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice. ( Aliabadi, M; Meshkani, R; Panahi, G; Tehrani, SS; Zamani-Garmsiri, F, 2021) |
| "Although the results of our and other studies show that baicalin can enhance glucose uptake and insulin sensitivity in skeletal muscle and adipocytes of mice, the specific metabolic contribution of baicalin on hepatic insulin resistance and gluconeogenic activity is still unclear." | 7.91 | Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway. ( Bo, P; Bu, L; Fang, P; Gu, X; Shi, M; Sun, Y; Zhang, Z, 2019) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 7.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| " This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 7.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
| " This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance." | 7.81 | The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. ( Krysiak, R; Okopien, B; Okrzesik, J, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "We aimed to evaluate the effects of aerobic exercise training (4 days) and metformin exposure on acute glucose intolerance after dexamethasone treatment in rats." | 7.81 | Effects of exercise and metformin on the prevention of glucose intolerance: a comparative study. ( Bersani-Amado, CA; Cuman, RK; Ferraro, ZM; Hintze, LJ; Molena-Fernandes, C; Nardo, N, 2015) |
| " Many of these compounds, including olanzapine, cause metabolic side-effects such as impaired glucose tolerance and insulin resistance." | 7.80 | Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. ( Asiri, Y; Barr, AM; Boyda, HN; Honer, WG; Lo, R; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 7.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "This study analyzed the metabolic effects of dietary advice to follow calorie-restricted low-glycaemic index diet with metformin in overweight / obese impaired glucose tolerance subjects." | 7.80 | Improved metabolic response after 16 weeks of calorie-restricted low-glycaemic index diet and metformin in impaired glucose tolerance subjects. ( Augusto Casulari, L; Gonçalves Reis, CE; Macedo da Costa, TH; Pires da Silva, FV, 2014) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 7.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| " In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels." | 7.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| "In the Canadian Normoglycemia Outcome Evaluation (CANOE) trial, low-dose rosiglitazone/metformin reduced the risk of diabetes in subjects with impaired glucose tolerance by 66% over a median of 3." | 7.77 | Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. ( Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B, 2011) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 7.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| " In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0." | 7.71 | [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]. ( Scheen, AJ, 2001) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 7.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 6.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| "The primary outcome measure was type 2 diabetes as diagnosed using World Health Organization criteria." | 6.72 | The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). ( Bhaskar, AD; Mary, S; Mukesh, B; Ramachandran, A; Snehalatha, C; Vijay, V, 2006) |
| "Hyperglycemia is a known exacerbating factor in ischemic stroke." | 6.47 | [Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress]. ( Fujita-Hamabe, W; Harada, S; Tokuyama, S, 2011) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 6.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 5.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 5.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 5.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| " In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment." | 5.48 | Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. ( Fernandez, E; Liu, Y; Salmon, AB; Strong, R; Weiss, R, 2018) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 5.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 5.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 5.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 5.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| "A single center parallel double-blind randomized clinical trial with 24 months of follow-up in patients with impaired glucose tolerance plus two T2D risk factors which were randomized to linagliptin 5 mg + metformin 1700 mg daily + lifestyle (LM group) or metformin 1700 mg daily + lifestyle (M group)." | 5.34 | The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. ( Aguilar-García, A; Álvarez-Canales, M; Angulo-Romero, F; Durán-Pérez, EG; Evia-Viscarra, ML; Farfán-Vázquez, D; Folli, F; Guardado-Mendoza, R; Jiménez-Ceja, LM; Martínez-López, YE; Montes de Oca-Loyola, ML; Salazar-López, SS; Suárez-Pérez, EL, 2020) |
| "To determine the separated and combined effects of metformin and exercise on insulin sensitivity and free-living glycemic control in overweight individuals with prediabetes/type 2 diabetes (T2DM)." | 5.34 | Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. ( Mora-Rodríguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2020) |
| "Transplantation and Diabetes (Transdiab) is a single-centre, unblinded, pilot randomised controlled trial assessing the feasibility, tolerability and efficacy of metformin after renal transplantation in patients with impaired glucose tolerance (IGT)." | 5.30 | Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. ( Alnasrallah, B; Chan, LW; Goh, TL; Manley, P; Pilmore, H, 2019) |
| " The RISE Pediatric Medication Study compared two approaches-glargine followed by metformin and metformin alone-in preserving or improving β-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal." | 5.27 | Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. ( , 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 5.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| " The models can be used by overweight and obese adults with fasting hyperglycemia and impaired glucose tolerance to facilitate personalized decision-making by allowing them to explicitly weigh the benefits and feasibility of the lifestyle and metformin interventions." | 5.24 | Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. ( Barrett-Connor, E; Dabelea, DM; Edelstein, SL; Herman, WH; Horton, E; Kahn, SE; Knowler, WC; Lorenzo, C; Mather, KJ; Pan, Q; Perreault, L; Pi-Sunyer, X; Venditti, E; Ye, W, 2017) |
| "This study tests the effectiveness of expert guidelines for diabetes prevention: lifestyle intervention with addition of metformin, when required, among people with prediabetes." | 5.22 | The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial. ( Ali, MK; Anjana, RM; Mohan, V; Narayan, KM; Ranjani, H; Staimez, LR; Weber, MB, 2016) |
| "The Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke trial (MAAS trial) is a phase II, multicenter, randomized, controlled, open-label trial with blinded outcome assessment." | 5.20 | Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. ( Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA, 2015) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 80 patients with isolated impaired glucose tolerance and normal plasma lipids who complied with lifestyle modifications and received chronic fenofibrate treatment." | 5.17 | Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study included 43 patients with isolated impaired glucose tolerance and normal plasma lipids who had been treated for at least 6 months with micronized fenofibrate (200 mg daily)." | 5.17 | Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 5.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "The Indian Diabetes Prevention Programme-1 (IDPP-1) showed that lifestyle modification (LSM) and metformin were effective for primary prevention of diabetes in subjects with impaired glucose tolerance (IGT)." | 5.14 | Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). ( Mary, S; Nanditha, A; Ramachandran, A; Sathish Kumar, CK; Selvam, S; Shetty, SB; Snehalatha, C, 2009) |
| "The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin." | 5.14 | Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. ( Baccara-Dinet, M; Charles, MA; Diouf, I; Eschwege, E; Fontbonne, A, 2009) |
| "In this double-blind, randomised controlled trial undertaken in clinics in Canadian centres, 207 patients with impaired glucose tolerance were randomly assigned to receive combination rosiglitazone (2 mg) and metformin (500 mg) twice daily or matching placebo for a median of 3." | 5.14 | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. ( Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Qi, Y; Raboud, J; Retnakaran, RR; Zinman, B, 2010) |
| "In subjects with impaired glucose tolerance (IGT) who participated in the Indian Diabetes Prevention Programme (IDPP), abnormalities related to body mass index, waist circumference (WC), blood pressure (BP), lipid profile and electrocardiography were analysed (at baseline and third-year follow-up) in control, lifestyle modification (LSM), metformin (MET) and LSM + MET groups." | 5.13 | Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. ( Joshi, VV; Mary, S; Ramachandran, A; Snehalatha, C, 2008) |
| " For this reason, we investigated circulating bioactive lipopolysaccharide and the effects of changing insulin action-after treatment with an insulin sensitizer (metformin)-on circulating BPI in subjects with glucose intolerance." | 5.12 | Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. ( Biarnés, J; Fernández-Real, JM; Gubern, C; López-Bermejo, A; Ricart, W; Vendrell, J, 2006) |
| "Height, weight, waist circumference, hip circumference, and skinfolds were measured at baseline in 3234 participants enrolled in a randomized clinical trial to treat individuals with impaired glucose tolerance with placebo, metformin, or a lifestyle modification program." | 5.12 | Relationship of body size and shape to the development of diabetes in the diabetes prevention program. ( , 2006) |
| " The Diabetes Prevention Program (DPP) recruited and randomized individuals with impaired glucose tolerance to treatment with placebo, metformin, or lifestyle modification." | 5.12 | Body size and shape changes and the risk of diabetes in the diabetes prevention program. ( Barrett-Connor, E; Bray, GA; Fujimoto, WY; Haffner, S; Hanson, R; Hill, JO; Hubbard, V; Jablonski, KA; Kriska, A; Pi-Sunyer, FX; Stamm, E, 2007) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 5.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 5.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 5.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "Metformin attenuates hyperglycemia and increases muscle protein synthesis in severely burned patients, thereby indicating a metabolic link between hyperglycemia and muscle loss following severe injury." | 5.11 | Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. ( Gore, DC; Herndon, DN; Sanford, A; Wolf, SE; Wolfe, RR, 2005) |
| "Metformin is able to reverse insulin resistance and hyperglycemia in high-risk subjects for type 2 diabetes mellitus independently of the effects on tumor necrosis factor alpha system activity." | 5.11 | Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. ( Biarnés, J; del Mar García, M; Fernández-Castañer, M; Fernández-Real, JM; Ricart, W; Soler, J, 2005) |
| "Hypertension was present in 30% of participants at study entry and then increased in the placebo and metformin groups, although it significantly decreased with intensive lifestyle intervention." | 5.11 | Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. ( Fowler, S; Goldberg, R; Haffner, S; Marcovina, S; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| " The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance." | 5.11 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. ( Barrett-Connor, E; Crandall, J; Fowler, S; Goldberg, R; Haffner, S; Horton, E; Marcovina, S; Mather, K; Orchard, T; Ratner, R; Temprosa, M, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 5.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "To evaluate the effect of metformin on glucose metabolism, insulin sensitivity and rate of conversion diabetes in people with impaired glucose tolerance (IGT)." | 5.09 | Effect of metformin on patients with impaired glucose tolerance. ( Deng, XX; Li, CL; Lu, JM; Pan, CY; Wang, HY; Wang, HZ; Wang, JH; Xia, FC; Zhu, Y, 1999) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 5.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "To assess the effect of metformin on insulin sensitivity, glucose tolerance and components of the metabolic syndrome in patients with impaired glucose tolerance (IGT)." | 5.09 | Metabolic effects of metformin in patients with impaired glucose tolerance. ( Eriksson, JG; Forsén, B; Groop, L; Gullström, M; Häggblom, M; Lehtovirta, M; Taskinen, MR, 2001) |
| "We included randomised controlled trials (RCTs) with a duration of one year or more comparing metformin with any pharmacological glucose-lowering intervention, behaviour-changing intervention, placebo or standard care in people with impaired glucose tolerance, impaired fasting glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or combinations of these." | 5.01 | Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. ( Chi, Y; Hemmingsen, B; Madsen, KS; Metzendorf, MI; Richter, B, 2019) |
| " Insulin resistance drives islet cell upregulation, manifested by elevated glucagon and c-peptide levels, early in the transition to IGT." | 4.88 | Insulin resistance in type 2 diabetic youth. ( Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ, 2012) |
| " Both of them clearly demonstrate the possibility to delay and/or prevent the onset of type 2 diabetes in at high-risk subjects with impaired glucose tolerance, through changes in lifestyle (dietary intervention, weight reduction, increased physical activity) or drug treatment (metformin, acarbose, orlistat)." | 4.82 | [Is it possible to prevent type 2 diabetes?]. ( Laville, M, 2003) |
| " Although no clinical trials over 6 months in duration have assessed the long-term efficacy of metformin use in adolescents, short-term trials have shown promising effects in lowering insulin secretion, improving insulin sensitivity, restoring normal menstrual cycles, and correcting lipid abnormalities." | 4.81 | Polycystic ovary syndrome in adolescents. ( Kent, SC; Legro, RS, 2002) |
| " Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
| "Metformin is a first-line drug for DM2 treatment and prevention, but its complex effect on impaired glucose tolerance (IGT), including its influence on myocardial resistance to ischemia-reperfusion injury, is not completely studied." | 4.12 | Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome. ( Chernikova, A; Dmitriev, A; Ermolenko, E; Galagudza, M; Gladyshev, N; Karonova, T; Kotyleva, M; Lavrenova, N; Minasian, S; Simanenkova, A; Suvorov, A; Timkina, N; Voropaeva, L, 2022) |
| "Although the beneficial effects of metformin (MET) and genistein in ameliorating inflammation have been elucidated, their combined impacts on skeletal muscle inflammation have not been clearly understood." | 4.02 | Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice. ( Aliabadi, M; Meshkani, R; Panahi, G; Tehrani, SS; Zamani-Garmsiri, F, 2021) |
| "Although the results of our and other studies show that baicalin can enhance glucose uptake and insulin sensitivity in skeletal muscle and adipocytes of mice, the specific metabolic contribution of baicalin on hepatic insulin resistance and gluconeogenic activity is still unclear." | 3.91 | Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway. ( Bo, P; Bu, L; Fang, P; Gu, X; Shi, M; Sun, Y; Zhang, Z, 2019) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 3.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| " This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 3.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
| " This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance." | 3.81 | The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. ( Krysiak, R; Okopien, B; Okrzesik, J, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| "Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin's PC growth inhibition in the context of a prediabetic state is unknown." | 3.81 | Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. ( Cifarelli, V; Devlin, KL; Dunlap, SM; Huang, J; Hursting, SD; Kaaks, R; Lashinger, LM; Pollak, MN, 2015) |
| "We aimed to evaluate the effects of aerobic exercise training (4 days) and metformin exposure on acute glucose intolerance after dexamethasone treatment in rats." | 3.81 | Effects of exercise and metformin on the prevention of glucose intolerance: a comparative study. ( Bersani-Amado, CA; Cuman, RK; Ferraro, ZM; Hintze, LJ; Molena-Fernandes, C; Nardo, N, 2015) |
| " Many of these compounds, including olanzapine, cause metabolic side-effects such as impaired glucose tolerance and insulin resistance." | 3.80 | Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. ( Asiri, Y; Barr, AM; Boyda, HN; Honer, WG; Lo, R; Pang, CC; Procyshyn, RM; Wang, CK; Wu, C, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 3.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "This study analyzed the metabolic effects of dietary advice to follow calorie-restricted low-glycaemic index diet with metformin in overweight / obese impaired glucose tolerance subjects." | 3.80 | Improved metabolic response after 16 weeks of calorie-restricted low-glycaemic index diet and metformin in impaired glucose tolerance subjects. ( Augusto Casulari, L; Gonçalves Reis, CE; Macedo da Costa, TH; Pires da Silva, FV, 2014) |
| "Chronic metformin treatment improved the glycemic homeostasis in pre-diabetic MSG-rats, glucose intolerance, tissue insulin resistance, hyperinsulinemia and decreased the fat tissue accretion." | 3.80 | Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement. ( Agostinho, AR; Barella, LF; Beraldi, EJ; de Castro Prado, MA; de Oliveira, JC; de Sant'Anna, JR; de Souza, CO; de Souza, HM; Franco, CC; Gravena, C; Malta, A; Mathias, PC; Miranda, RA; Prates, KV; Tófolo, LP; Torrezan, R; Trombini, AB, 2014) |
| "The October 2010 ESHRE/ASRM polycystic ovary syndrome (PCOS) workshop concluded: (1) all combined oral contraceptives (COC) appear to have equal efficacy for PCOS, (2) addition of antiandrogens (spironolactone) to COCs has little treatment benefit and (3) metformin does not improve the live-birth rate and should only be used with impaired glucose tolerance." | 3.79 | Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. ( Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 3.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| " In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels." | 3.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| "In the Canadian Normoglycemia Outcome Evaluation (CANOE) trial, low-dose rosiglitazone/metformin reduced the risk of diabetes in subjects with impaired glucose tolerance by 66% over a median of 3." | 3.77 | Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. ( Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B, 2011) |
| " As a result, mice with hepatic knockout of p110alpha display reduced insulin sensitivity, impaired glucose tolerance, and increased gluconeogenesis, hypolipidemia, and hyperleptinemia." | 3.76 | Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. ( Asano, T; Farese, RV; Kahn, CR; Kondo, T; Liu, P; Sajan, MP; Smyth, G; Sopasakis, VR; Suzuki, R; Tran, TT; Winnay, J; Zhao, JJ, 2010) |
| "Impaired glucose tolerance in obese youth is a reversible abnormality by lifestyle modification with or without metformin." | 3.76 | Successful strategy to improve glucose tolerance in Thai obese youth. ( Kiattisakthavee, P; Likitmaskul, S; Nakavachara, P; Numbenjapon, N; Santiprabhob, J; Wongarn, R, 2010) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| " In the present study, we compared the plasma levels and adipose tissue expression of adiponectin in subjects with normal (NGT) and impaired glucose tolerance (IGT) and also studied the effects of metformin and pioglitazone on plasma and adipose tissue mRNA level of adiponectin in IGT subjects." | 3.73 | Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. ( Elbein, SC; Kern, PA; Miles, LM; Rasouli, N; Yao-Borengasser, A, 2006) |
| "To evaluate the cost-effectiveness of preventive treatment on diabetes, using metformin or acarbose among patients with impaired glucose tolerance." | 3.72 | [Cost-effective analysis of preventive treatment on diabetes]. ( Chen, SY; Hu, Y; Wang, JY, 2004) |
| "To compare the health and economic outcomes of using acarbose, an intensive lifestyle modification programme, metformin or no intervention to prevent progression to diabetes in Canadian individuals with impaired glucose tolerance (IGT)." | 3.72 | Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. ( Caro, I; Caro, JJ; Getsios, D; Klittich, WS; O'Brien, JA, 2004) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 3.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| " In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0." | 3.71 | [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]. ( Scheen, AJ, 2001) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 3.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| " A higher proportion of participants in the metformin plus lifestyle intervention group reported adverse events than in the lifestyle intervention alone group, primarily due to more gastrointestinal adverse events." | 3.30 | Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled t ( Bai, J; Cheng, W; Dong, L; Du, J; Fang, H; Gong, Q; Hou, F; Ji, L; Kuang, H; Li, G; Li, Q; Li, Y; Lian, X; Liu, Y; Lu, Q; Qi, L; Ren, W; Shen, S; Sun, N; Wang, X; Wang, Y; Wu, D; Yan, S; Yang, Z; Zhang, L; Zhang, Y, 2023) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 2.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| "A past history of gestational diabetes mellitus (GDM) confers a very high risk of postpartum development of diabetes, particularly type 2 diabetes." | 2.73 | Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. ( Bennett, PH; Christophi, CA; Dabelea, D; Fowler, S; Kahn, SE; Metzger, BE; Pi-Sunyer, X; Ratner, RE, 2008) |
| "Lysine carriers were less protected by 1-year metformin treatment than E/E homozygotes (P < 0." | 2.73 | Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. ( Altshuler, D; Dabelea, D; Florez, JC; Franks, PW; Hamman, RF; Jablonski, KA; Kahn, SE; Knowler, WC; Nathan, DM, 2007) |
| "Obesity has health consequences going beyond glucose elevation." | 2.72 | Pharmacotherapeutic options for prediabetes. ( Rendell, M, 2021) |
| "The primary outcome measure was type 2 diabetes as diagnosed using World Health Organization criteria." | 2.72 | The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). ( Bhaskar, AD; Mary, S; Mukesh, B; Ramachandran, A; Snehalatha, C; Vijay, V, 2006) |
| "Several studies have demonstrated that type 2 diabetes mellitus (DM) can be prevented/delayed in subjects with impaired glucose tolerance (IGT) by using pharmacologic agents and/or lifestyle interventions." | 2.72 | Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. ( Gerstein, HC; Hanley, AJ; Harris, SB; Neuman, J; Raboud, JM; Young, TK; Zinman, B, 2006) |
| "Metformin was shown to be beneficial in the clearance of postprandial lipoproteins in nondiabetic individuals who were mildly overweight and glucose intolerant." | 2.68 | Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. ( Charach, G; Grosskopf, I; Iaina, A; Maharshak, N; Mor, R; Ringel, Y; Weintraub, M, 1997) |
| "The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development." | 2.61 | Does diabetes prevention translate into reduced long-term vascular complications of diabetes? ( Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH, 2019) |
| "The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide." | 2.55 | Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. ( Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP, 2017) |
| "Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients." | 2.48 | Diabetes and pancreatic cancer. ( Chari, ST; Muniraj, T, 2012) |
| "Hyperglycemia is a known exacerbating factor in ischemic stroke." | 2.47 | [Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress]. ( Fujita-Hamabe, W; Harada, S; Tokuyama, S, 2011) |
| "Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)." | 2.44 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. ( Fonseca, VA, 2007) |
| "Polycystic ovary syndrome is a diagnosis of exclusion of other causes of hyperandrogenism." | 2.43 | Polycystic ovary syndrome--a management update. ( Costello, MF, 2005) |
| "Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were not possible." | 2.43 | Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. ( Akkermans, RP; De Grauw, WJ; Lucassen, PL; Van de Laar, FA; Van de Lisdonk, EH, 2006) |
| "Treatment with metformin significantly reduced the incidence of diabetes in subjects with IGT and high-normal fasting plasma glucose in the DPP." | 2.42 | The potential of metformin for diabetes prevention. ( Slama, G, 2003) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 2.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| "Individuals with type 2 diabetes mellitus (T2DM) have a greater risk of bone fracture compared with those with normal glucose tolerance (NGT)." | 1.91 | Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin. ( Donnelly, E; Lekkala, S; Moseley, KF; Sacher, SE; Taylor, EA; Williams, RM, 2023) |
| "Metformin, a frontline therapy for type 2 diabetes and related metabolic diseases, results in variable outcomes." | 1.91 | Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice. ( Bernier, A; de Lartigue, G; Rourk, K; Singh, A, 2023) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 1.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| "Metformin was administered intragastrically, and aerobic exercise was performed using treadmill with 7-12 m/min, 30-40 min/day, 5 days/week." | 1.62 | Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments. ( Liu, J; Lu, J; Tang, Q; Wang, X; Zhang, L; Zhang, Y, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 1.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| "Glycemic traits and type 2 diabetes unlikely cause breast and prostate cancer." | 1.51 | Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. ( Au Yeung, SL; Schooling, CM, 2019) |
| " In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment." | 1.48 | Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. ( Fernandez, E; Liu, Y; Salmon, AB; Strong, R; Weiss, R, 2018) |
| "Metformin is a first-line drug for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear." | 1.48 | Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. ( Hughey, CC; Hunter, RW; Jessen, N; Lantier, L; Peggie, M; Sakamoto, K; Sicheri, F; Sundelin, EI; Wasserman, DH; Zeqiraj, E, 2018) |
| "Metformin treatment remarkably improved liver function, alleviated lipid peroxidation and histological damages of the liver, and ameliorated glucose intolerance and insulin resistance." | 1.43 | Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. ( Chen, F; Liu, Y; Ping, J; Ruo, R; Shou, Q; Xu, H; Zhou, Y, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 1.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "Myocardial fibrosis is a key process in diabetic cardiomyopathy." | 1.39 | Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. ( Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J, 2013) |
| "Metformin has been shown to be effective therapy and could be used more widely in obese adolescents with hyperandrogenemia, a forerunner of PCOS." | 1.38 | Should all women with PCOS be treated for insulin resistance? ( Dunaif, A; Marshall, JC, 2012) |
| "Metformin treatment is useful to improve insulin resistance in DM1." | 1.38 | [Glucose intolerance in myotonic dystrophy type 1]. ( Goto, T; Kon, S; Oyama, Y; Takada, H, 2012) |
| "Metformin treatment also improved hyperleptinemia, whereas pioglitazone was ineffective." | 1.36 | Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. ( Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T, 2010) |
| " Our objectives were to assess the ability of rainbow trout to deal with a glucose load and to improve glucose utilization in fish receiving a chronic administration of insulin plus metformin treatments." | 1.35 | Glucose homeostasis is impaired by a paradoxical interaction between metformin and insulin in carnivorous rainbow trout. ( Panserat, S; Polakof, S; Skiba-Cassy, S, 2009) |
| "Impaired glucose tolerance is defined as two-hour glucose levels of 140 to 199 mg per dL (7." | 1.32 | Impaired glucose tolerance and impaired fasting glucose. ( Disraeli, P; McGregor, T; Rao, SS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (5.08) | 18.2507 |
| 2000's | 66 (33.50) | 29.6817 |
| 2010's | 93 (47.21) | 24.3611 |
| 2020's | 28 (14.21) | 2.80 |
| Authors | Studies |
|---|---|
| Hufnagel, A | 1 |
| Fernandez-Twinn, DS | 1 |
| Blackmore, HL | 1 |
| Ashmore, TJ | 1 |
| Heaton, RA | 1 |
| Jenkins, B | 1 |
| Koulman, A | 1 |
| Hargreaves, IP | 1 |
| Aiken, CE | 1 |
| Ozanne, SE | 1 |
| Osei, E | 2 |
| Zandbergen, A | 1 |
| Brouwers, PJAM | 1 |
| Mulder, LJMM | 1 |
| Koudstaal, P | 1 |
| Lingsma, H | 1 |
| Dippel, DWJ | 1 |
| den Hertog, H | 1 |
| Lu, J | 1 |
| Liu, J | 2 |
| Zhang, L | 3 |
| Wang, X | 6 |
| Zhang, Y | 5 |
| Tang, Q | 1 |
| Ermolenko, E | 1 |
| Simanenkova, A | 2 |
| Voropaeva, L | 1 |
| Lavrenova, N | 1 |
| Kotyleva, M | 1 |
| Minasian, S | 2 |
| Chernikova, A | 1 |
| Timkina, N | 2 |
| Gladyshev, N | 1 |
| Dmitriev, A | 1 |
| Suvorov, A | 1 |
| Galagudza, M | 2 |
| Karonova, T | 2 |
| Utzschneider, KM | 3 |
| Ehrmann, DA | 4 |
| Arslanian, SA | 3 |
| Barengolts, E | 2 |
| Buchanan, TA | 4 |
| Caprio, S | 3 |
| Edelstein, SL | 9 |
| Hannon, TS | 2 |
| Kahn, SE | 10 |
| Kozedub, A | 1 |
| Mather, KJ | 10 |
| Nadeau, KJ | 4 |
| Sam, S | 1 |
| Tripputi, M | 2 |
| Xiang, AH | 2 |
| El Ghormli, L | 1 |
| Pagotto, V | 1 |
| Posadas Martínez, ML | 1 |
| Salzberg, S | 1 |
| Pochettino, PA | 1 |
| Yeung, KF | 1 |
| Lee, YQ | 1 |
| Chong, MFF | 1 |
| Gandhi, M | 1 |
| Lam, AYR | 1 |
| Julianty, S | 1 |
| Tan, GCS | 1 |
| Ho, ETL | 1 |
| Goh, SY | 1 |
| Tan, GSW | 1 |
| Shum, EJW | 1 |
| Finkelstein, EA | 1 |
| Jafar, TH | 1 |
| van Dam, RM | 1 |
| Teoh, YL | 1 |
| Thumboo, J | 1 |
| Bee, YM | 1 |
| Lekkala, S | 2 |
| Sacher, SE | 2 |
| Taylor, EA | 2 |
| Williams, RM | 2 |
| Moseley, KF | 2 |
| Donnelly, E | 2 |
| Singh, A | 1 |
| Rourk, K | 1 |
| Bernier, A | 1 |
| de Lartigue, G | 1 |
| Shen, S | 2 |
| Dong, L | 2 |
| Li, Q | 3 |
| Ren, W | 2 |
| Li, Y | 2 |
| Bai, J | 1 |
| Gong, Q | 1 |
| Kuang, H | 2 |
| Qi, L | 2 |
| Lu, Q | 1 |
| Cheng, W | 2 |
| Liu, Y | 3 |
| Yan, S | 2 |
| Wu, D | 1 |
| Fang, H | 1 |
| Hou, F | 1 |
| Wang, Y | 1 |
| Yang, Z | 1 |
| Lian, X | 1 |
| Du, J | 1 |
| Sun, N | 2 |
| Ji, L | 2 |
| Li, G | 2 |
| Garrib, A | 1 |
| Kivuyo, S | 1 |
| Bates, K | 1 |
| Ramaiya, K | 1 |
| Wang, D | 1 |
| Majaliwa, E | 1 |
| Simbauranga, R | 1 |
| Charles, G | 1 |
| van Widenfelt, E | 1 |
| Luo, H | 1 |
| Alam, U | 1 |
| Nyirenda, MJ | 1 |
| Jaffar, S | 1 |
| Mfinanga, S | 1 |
| Fang, P | 1 |
| Sun, Y | 2 |
| Gu, X | 1 |
| Shi, M | 1 |
| Bo, P | 1 |
| Zhang, Z | 1 |
| Bu, L | 1 |
| Madsen, KS | 1 |
| Chi, Y | 1 |
| Metzendorf, MI | 3 |
| Richter, B | 3 |
| Hemmingsen, B | 3 |
| Guardado-Mendoza, R | 1 |
| Salazar-López, SS | 1 |
| Álvarez-Canales, M | 1 |
| Farfán-Vázquez, D | 1 |
| Martínez-López, YE | 1 |
| Jiménez-Ceja, LM | 1 |
| Suárez-Pérez, EL | 1 |
| Angulo-Romero, F | 1 |
| Evia-Viscarra, ML | 1 |
| Montes de Oca-Loyola, ML | 1 |
| Durán-Pérez, EG | 1 |
| Folli, F | 1 |
| Aguilar-García, A | 1 |
| Au Yeung, SL | 1 |
| Schooling, CM | 1 |
| Mahlangu, TJ | 1 |
| Dludla, PV | 1 |
| Mxinwa, V | 1 |
| Mkandla, Z | 1 |
| Tiano, L | 1 |
| Louw, J | 1 |
| Mutize, T | 1 |
| Nyambuya, TM | 1 |
| Nkambule, BB | 1 |
| Ortega, JF | 1 |
| Morales-Palomo, F | 1 |
| Ramirez-Jimenez, M | 1 |
| Moreno-Cabañas, A | 1 |
| Mora-Rodríguez, R | 1 |
| Zhang, K | 1 |
| Bai, P | 1 |
| Dai, H | 1 |
| Deng, Z | 1 |
| Day, EA | 1 |
| Ford, RJ | 1 |
| Smith, BK | 1 |
| Mohammadi-Shemirani, P | 1 |
| Morrow, MR | 1 |
| Gutgesell, RM | 1 |
| Lu, R | 1 |
| Raphenya, AR | 1 |
| Kabiri, M | 1 |
| McArthur, AG | 1 |
| McInnes, N | 1 |
| Hess, S | 1 |
| Paré, G | 1 |
| Gerstein, HC | 4 |
| Steinberg, GR | 1 |
| Rendell, M | 1 |
| Zeitler, PS | 1 |
| Tao, T | 1 |
| Zhu, YC | 1 |
| Fu, JR | 1 |
| Wang, YY | 1 |
| Cai, J | 2 |
| Ma, JY | 1 |
| Xu, Y | 2 |
| Gao, YN | 1 |
| Fan, W | 1 |
| Liu, W | 1 |
| Frenkel, JDH | 1 |
| Ackart, DF | 1 |
| Todd, AK | 1 |
| DiLisio, JE | 1 |
| Hoffman, S | 1 |
| Tanner, S | 1 |
| Kiran, D | 1 |
| Murray, M | 1 |
| Chicco, A | 1 |
| Obregón-Henao, A | 1 |
| Podell, BK | 1 |
| Basaraba, RJ | 1 |
| Zamani-Garmsiri, F | 2 |
| Ghasempour, G | 1 |
| Aliabadi, M | 2 |
| Hashemnia, SMR | 1 |
| Emamgholipour, S | 1 |
| Meshkani, R | 2 |
| Aroda, VR | 1 |
| Christophi, CA | 3 |
| Perreault, L | 3 |
| Kim, C | 6 |
| Golden, SH | 5 |
| Horton, E | 4 |
| Vlasov, T | 1 |
| Shpilevaya, O | 1 |
| Khalzova, A | 1 |
| Shimshilashvili, A | 1 |
| Timofeeva, V | 1 |
| Samsonov, D | 1 |
| Borshchev, Y | 1 |
| Brooks-Worrell, BM | 1 |
| Tjaden, AH | 1 |
| Palomino, B | 1 |
| Arslanian, S | 1 |
| Atkinson, K | 1 |
| Palmer, JP | 1 |
| Solomon, TPJ | 1 |
| Thyfault, JP | 1 |
| Haus, JM | 1 |
| Karstoft, K | 1 |
| DI Giuseppe, G | 1 |
| Ciccarelli, G | 1 |
| Cefalo, CM | 1 |
| Cinti, F | 1 |
| Moffa, S | 1 |
| Impronta, F | 1 |
| Capece, U | 1 |
| Pontecorvi, A | 1 |
| Giaccari, A | 1 |
| Mezza, T | 1 |
| Panahi, G | 1 |
| Tehrani, SS | 1 |
| Fu, Y | 1 |
| Mu, YM | 2 |
| Huang, Y | 1 |
| Xuan, J | 1 |
| Dy, ABC | 1 |
| Tassone, F | 1 |
| Eldeeb, M | 1 |
| Salcedo-Arellano, MJ | 1 |
| Tartaglia, N | 1 |
| Hagerman, R | 1 |
| Sonne, DP | 1 |
| Nouhjah, S | 1 |
| Shahbazian, H | 1 |
| Shahbazian, N | 1 |
| Jahanshahi, A | 1 |
| Jahanfar, S | 1 |
| Cheraghian, B | 1 |
| Wang, Z | 1 |
| Xu, D | 1 |
| Huang, L | 1 |
| Zhang, T | 1 |
| Wang, J | 1 |
| Chen, Q | 1 |
| Kong, L | 1 |
| Zhou, X | 1 |
| González-Heredia, T | 1 |
| Hernández-Corona, DM | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Mesmar, B | 1 |
| Poola-Kella, S | 1 |
| Malek, R | 1 |
| Dabelea, D | 3 |
| Kalyani, RR | 1 |
| Bray, GA | 4 |
| Pi-Sunyer, X | 4 |
| Darwin, CH | 1 |
| Yalamanchi, S | 1 |
| Barrett-Connor, E | 10 |
| Boyko, EJ | 1 |
| Alnasrallah, B | 2 |
| Pilmore, H | 2 |
| Manley, P | 2 |
| Choi, RY | 1 |
| Ham, JR | 1 |
| Lee, HI | 1 |
| Cho, HW | 1 |
| Choi, MS | 1 |
| Park, SK | 2 |
| Lee, J | 1 |
| Kim, MJ | 1 |
| Seo, KI | 1 |
| Lee, MK | 1 |
| Herman, WH | 2 |
| Pan, Q | 1 |
| Dabelea, DM | 1 |
| Knowler, WC | 4 |
| Lorenzo, C | 1 |
| Venditti, E | 1 |
| Ye, W | 1 |
| Tieu, J | 1 |
| Coat, S | 1 |
| Hague, W | 1 |
| Middleton, P | 1 |
| Shepherd, E | 1 |
| Elkind-Hirsch, KE | 1 |
| Paterson, MS | 1 |
| Shaler, D | 1 |
| Gutowski, HC | 1 |
| Weiss, R | 1 |
| Fernandez, E | 1 |
| Strong, R | 1 |
| Salmon, AB | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| Mroueh, A | 1 |
| Kaplan, A | 1 |
| Mougharbil, N | 1 |
| Eid, AH | 1 |
| Zouein, FA | 1 |
| El-Yazbi, AF | 1 |
| Hunter, RW | 1 |
| Hughey, CC | 1 |
| Lantier, L | 1 |
| Sundelin, EI | 1 |
| Peggie, M | 1 |
| Zeqiraj, E | 1 |
| Sicheri, F | 1 |
| Jessen, N | 1 |
| Wasserman, DH | 1 |
| Sakamoto, K | 1 |
| Trigo, E | 1 |
| Martinez, M | 1 |
| Katkhouda, N | 1 |
| Beale, E | 1 |
| Wu, J | 1 |
| Chow, T | 1 |
| Montgomery, C | 1 |
| Nayak, KS | 1 |
| Hendee, F | 1 |
| Sun, L | 1 |
| Xie, C | 1 |
| Wang, G | 1 |
| Wu, Y | 1 |
| Wu, Q | 1 |
| Deng, Y | 1 |
| Xia, J | 1 |
| Chen, B | 1 |
| Zhang, S | 1 |
| Yun, C | 1 |
| Lian, G | 1 |
| Zhang, X | 1 |
| Zhang, H | 1 |
| Bisson, WH | 1 |
| Shi, J | 1 |
| Gao, X | 1 |
| Ge, P | 1 |
| Liu, C | 1 |
| Krausz, KW | 1 |
| Nichols, RG | 1 |
| Rimal, B | 1 |
| Patterson, AD | 1 |
| Gonzalez, FJ | 1 |
| Jiang, C | 1 |
| Moelands, SV | 1 |
| Lucassen, PL | 2 |
| Akkermans, RP | 2 |
| De Grauw, WJ | 2 |
| Van de Laar, FA | 2 |
| Opdebeeck, B | 1 |
| Maudsley, S | 1 |
| Azmi, A | 1 |
| De Maré, A | 1 |
| De Leger, W | 1 |
| Meijers, B | 1 |
| Verhulst, A | 1 |
| Evenepoel, P | 1 |
| D'Haese, PC | 1 |
| Neven, E | 1 |
| Goh, TL | 1 |
| Chan, LW | 1 |
| Pratte, KA | 1 |
| Johnson, A | 1 |
| Beals, J | 1 |
| Bullock, A | 1 |
| Manson, SM | 1 |
| Jiang, L | 1 |
| Nathan, DM | 2 |
| Bennett, PH | 3 |
| Crandall, JP | 3 |
| Goldberg, RB | 3 |
| Mudaliar, S | 1 |
| Orchard, TJ | 3 |
| Temprosa, M | 4 |
| White, NH | 1 |
| Malin, SK | 2 |
| Nightingale, J | 1 |
| Choi, SE | 1 |
| Chipkin, SR | 1 |
| Braun, B | 2 |
| Krysiak, R | 4 |
| Gdula-Dymek, A | 3 |
| Okopień, B | 4 |
| Schlechte, JA | 1 |
| Nan, B | 4 |
| Kong, S | 4 |
| Goldberg, R | 4 |
| Paruthi, J | 1 |
| Gill, N | 1 |
| Mantzoros, CS | 1 |
| Stentz, FB | 1 |
| Murphy, MB | 1 |
| Kitabchi, AE | 1 |
| Harada, S | 2 |
| Yamazaki, Y | 1 |
| Tokuyama, S | 2 |
| Kim, D | 1 |
| Lee, JE | 1 |
| Jung, YJ | 1 |
| Lee, AS | 1 |
| Lee, S | 1 |
| Kim, SH | 1 |
| Park, BH | 1 |
| Kim, W | 1 |
| Kang, KP | 1 |
| Florez, H | 1 |
| Temprosa, MG | 1 |
| Marcovina, SM | 1 |
| Saudek, C | 2 |
| Pi-Sunyer, XF | 1 |
| Ratner, RE | 4 |
| Boyda, HN | 2 |
| Procyshyn, RM | 2 |
| Asiri, Y | 1 |
| Wu, C | 2 |
| Wang, CK | 1 |
| Lo, R | 1 |
| Pang, CC | 2 |
| Honer, WG | 2 |
| Barr, AM | 2 |
| Picatoste, B | 1 |
| Ramírez, E | 1 |
| Caro-Vadillo, A | 1 |
| Iborra, C | 1 |
| Ares-Carrasco, S | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, O | 1 |
| Woo, SL | 1 |
| Xu, H | 2 |
| Li, H | 1 |
| Zhao, Y | 1 |
| Hu, X | 1 |
| Zhao, J | 1 |
| Guo, X | 1 |
| Guo, T | 1 |
| Botchlett, R | 1 |
| Qi, T | 1 |
| Pei, Y | 1 |
| Zheng, J | 1 |
| An, X | 1 |
| Chen, L | 2 |
| Xiao, X | 1 |
| Huo, Y | 1 |
| Macedo da Costa, TH | 1 |
| Pires da Silva, FV | 1 |
| Gonçalves Reis, CE | 1 |
| Augusto Casulari, L | 1 |
| Okrzesik, J | 1 |
| Franco, CC | 1 |
| Miranda, RA | 1 |
| de Oliveira, JC | 1 |
| Barella, LF | 1 |
| Agostinho, AR | 1 |
| Prates, KV | 1 |
| Malta, A | 1 |
| Trombini, AB | 1 |
| Torrezan, R | 1 |
| Gravena, C | 1 |
| Tófolo, LP | 1 |
| de Sant'Anna, JR | 1 |
| de Castro Prado, MA | 1 |
| de Souza, CO | 1 |
| de Souza, HM | 1 |
| Beraldi, EJ | 1 |
| Mathias, PC | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| Cifarelli, V | 1 |
| Lashinger, LM | 1 |
| Devlin, KL | 1 |
| Dunlap, SM | 1 |
| Huang, J | 1 |
| Kaaks, R | 1 |
| Pollak, MN | 1 |
| Hursting, SD | 1 |
| Matsumoto, Y | 1 |
| Ishii, M | 1 |
| Hayashi, Y | 1 |
| Miyazaki, S | 1 |
| Sugita, T | 1 |
| Sumiya, E | 1 |
| Sekimizu, K | 1 |
| Fonville, S | 1 |
| Zandbergen, AA | 1 |
| Brouwers, PJ | 1 |
| Mulder, LJ | 1 |
| Lingsma, HF | 1 |
| Dippel, DW | 1 |
| Koudstaal, PJ | 1 |
| den Hertog, HM | 1 |
| Molena-Fernandes, C | 1 |
| Bersani-Amado, CA | 1 |
| Ferraro, ZM | 1 |
| Hintze, LJ | 1 |
| Nardo, N | 1 |
| Cuman, RK | 1 |
| Zhou, Y | 1 |
| Ping, J | 1 |
| Shou, Q | 1 |
| Chen, F | 1 |
| Ruo, R | 1 |
| Krogh, J | 1 |
| Weber, MB | 1 |
| Ranjani, H | 1 |
| Staimez, LR | 1 |
| Anjana, RM | 1 |
| Ali, MK | 1 |
| Narayan, KM | 2 |
| Mohan, V | 1 |
| Cefalu, WT | 1 |
| Buse, JB | 1 |
| Tuomilehto, J | 1 |
| Fleming, GA | 1 |
| Ferrannini, E | 1 |
| Ramachandran, A | 7 |
| Raz, I | 1 |
| Rosenstock, J | 1 |
| Thomas, AP | 1 |
| Hoang, J | 1 |
| Vongbunyong, K | 1 |
| Nguyen, A | 1 |
| Rakshit, K | 1 |
| Matveyenko, AV | 1 |
| Tong, YZ | 1 |
| Tong, NW | 1 |
| Teng, WP | 1 |
| Zhao, JJ | 2 |
| Shan, ZY | 1 |
| Ning, G | 1 |
| Metzger, BE | 1 |
| Fowler, S | 3 |
| Ecker, JL | 1 |
| Haffner, S | 4 |
| Fowler, SE | 1 |
| Mather, K | 2 |
| Marcovina, S | 4 |
| Matulik, MJ | 1 |
| Price, D | 1 |
| Snehalatha, C | 6 |
| Mary, S | 3 |
| Selvam, S | 1 |
| Sathish Kumar, CK | 1 |
| Shetty, SB | 1 |
| Nanditha, A | 2 |
| Polsky, S | 1 |
| Howard, AA | 1 |
| Brown-Friday, J | 1 |
| Whittington, T | 1 |
| Foo, S | 1 |
| Ma, Y | 1 |
| Fontbonne, A | 1 |
| Diouf, I | 1 |
| Baccara-Dinet, M | 1 |
| Eschwege, E | 1 |
| Charles, MA | 1 |
| Omer, Z | 1 |
| Cetinkalp, S | 1 |
| Akyildiz, M | 1 |
| Yilmaz, F | 1 |
| Batur, Y | 1 |
| Yilmaz, C | 1 |
| Akarca, U | 1 |
| Polakof, S | 1 |
| Skiba-Cassy, S | 1 |
| Panserat, S | 1 |
| Rhee, MK | 1 |
| Herrick, K | 1 |
| Ziemer, DC | 1 |
| Vaccarino, V | 1 |
| Weintraub, WS | 1 |
| Kolm, P | 1 |
| Twombly, JG | 1 |
| Phillips, LS | 1 |
| Marchetti, P | 1 |
| Lupi, R | 1 |
| Del Guerra, S | 1 |
| Bugliani, M | 1 |
| D'Aleo, V | 1 |
| Occhipinti, M | 1 |
| Boggi, U | 1 |
| Marselli, L | 1 |
| Masini, M | 1 |
| Krakoff, J | 1 |
| Clark, JM | 1 |
| Wilson, C | 1 |
| Molitch, ME | 1 |
| Brancati, FL | 1 |
| Sopasakis, VR | 1 |
| Liu, P | 1 |
| Suzuki, R | 1 |
| Kondo, T | 1 |
| Winnay, J | 1 |
| Tran, TT | 1 |
| Asano, T | 1 |
| Smyth, G | 1 |
| Sajan, MP | 1 |
| Farese, RV | 1 |
| Kahn, CR | 1 |
| Arun, N | 1 |
| Shetty, AS | 1 |
| Matsui, Y | 1 |
| Hirasawa, Y | 1 |
| Sugiura, T | 1 |
| Toyoshi, T | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Gad, MZ | 1 |
| Ehssan, NA | 1 |
| Ghiet, MH | 1 |
| Wahman, LF | 1 |
| Zinman, B | 4 |
| Harris, SB | 4 |
| Neuman, J | 2 |
| Retnakaran, RR | 1 |
| Raboud, J | 1 |
| Qi, Y | 2 |
| Hanley, AJ | 4 |
| Mamas, MA | 1 |
| Deaton, C | 1 |
| Rutter, MK | 1 |
| Yuille, M | 1 |
| Williams, SG | 1 |
| Ray, SG | 1 |
| New, J | 1 |
| Gibson, JM | 1 |
| Neyses, L | 1 |
| Ferrante, G | 1 |
| Zavalloni, D | 1 |
| Corrada, E | 1 |
| Presbitero, P | 1 |
| Malaga, G | 1 |
| Miranda, JJ | 1 |
| Ceriani, E | 1 |
| Costantino, G | 1 |
| Casazza, G | 1 |
| Podda, GM | 1 |
| Kasabri, V | 1 |
| Afifi, FU | 1 |
| Hamdan, I | 1 |
| Numbenjapon, N | 1 |
| Nakavachara, P | 1 |
| Santiprabhob, J | 1 |
| Kiattisakthavee, P | 1 |
| Wongarn, R | 1 |
| Likitmaskul, S | 1 |
| Fujita-Hamabe, W | 1 |
| Retnakaran, R | 2 |
| Samith Shetty, A | 1 |
| Ye, C | 1 |
| Marshall, JC | 1 |
| Dunaif, A | 1 |
| Ragia, G | 1 |
| Manolopoulos, VG | 1 |
| Gómez-Díaz, RA | 1 |
| Talavera, JO | 1 |
| Pool, EC | 1 |
| Ortiz-Navarrete, FV | 1 |
| Solórzano-Santos, F | 1 |
| Mondragón-González, R | 1 |
| Valladares-Salgado, A | 1 |
| Cruz, M | 1 |
| Aguilar-Salinas, CA | 2 |
| Wacher, NH | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Celik, O | 1 |
| Acbay, O | 1 |
| Tse, L | 1 |
| Hawkes, E | 1 |
| Jin, CH | 1 |
| Rissanen, A | 1 |
| Howard, CP | 1 |
| Botha, J | 1 |
| Thuren, T | 1 |
| Mizokami-Stout, K | 1 |
| Cree-Green, M | 1 |
| Hawkins, JZ | 1 |
| Wing, D | 1 |
| Laughlin, GA | 2 |
| Randolph, JF | 2 |
| Fradkin, JE | 1 |
| Roberts, BT | 1 |
| Rodgers, GP | 1 |
| Labrie, F | 1 |
| Buschur, E | 1 |
| Takada, H | 1 |
| Oyama, Y | 1 |
| Kon, S | 1 |
| Goto, T | 1 |
| Muniraj, T | 1 |
| Chari, ST | 1 |
| Bird, ST | 1 |
| Hartzema, AG | 1 |
| Etminan, M | 1 |
| Brophy, JM | 1 |
| Delaney, JA | 1 |
| Nestler, JE | 1 |
| Pugeat, M | 1 |
| Laville, M | 1 |
| Vague, P | 1 |
| Schäfers, RF | 1 |
| Slama, G | 1 |
| Flores-Saenz, JL | 1 |
| Trujillo-Arriaga, HM | 1 |
| Rivas-Vilchis, JF | 1 |
| Mendez-Francisco, JD | 1 |
| Alarcon-Aguilar, FJ | 1 |
| Roman-Ramos, R | 1 |
| Zimmer, P | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Yasuda, N | 1 |
| Inoue, T | 1 |
| Nagakura, T | 1 |
| Yamazaki, K | 1 |
| Kira, K | 1 |
| Saeki, T | 1 |
| Tanaka, I | 1 |
| Bloomgarden, ZT | 1 |
| Rao, SS | 1 |
| Disraeli, P | 1 |
| McGregor, T | 1 |
| Hu, Y | 1 |
| Chen, SY | 1 |
| Wang, JY | 1 |
| Caballero, AE | 1 |
| Delgado, A | 1 |
| Herrera, AN | 1 |
| Castillo, JL | 1 |
| Cabrera, T | 1 |
| Gomez-Perez, FJ | 1 |
| Rull, JA | 1 |
| Caro, JJ | 1 |
| Getsios, D | 1 |
| Caro, I | 1 |
| Klittich, WS | 1 |
| O'Brien, JA | 1 |
| Rasouli, N | 4 |
| Raue, U | 1 |
| Miles, LM | 2 |
| Lu, T | 1 |
| Di Gregorio, GB | 1 |
| Elbein, SC | 2 |
| Kern, PA | 4 |
| Gore, DC | 1 |
| Wolf, SE | 1 |
| Sanford, A | 1 |
| Herndon, DN | 1 |
| Wolfe, RR | 1 |
| Biarnés, J | 2 |
| Fernández-Real, JM | 2 |
| Fernández-Castañer, M | 1 |
| del Mar García, M | 1 |
| Soler, J | 1 |
| Ricart, W | 2 |
| Hoerger, TJ | 1 |
| Brandle, M | 1 |
| Hicks, K | 1 |
| Sorensen, S | 1 |
| Zhang, P | 1 |
| Hamman, RF | 2 |
| Ackermann, RT | 1 |
| Engelgau, MM | 1 |
| Asakura, T | 1 |
| Ito, Y | 1 |
| Ishida, W | 1 |
| Satoh, J | 1 |
| Kusaka, I | 1 |
| Nagasaka, S | 1 |
| Ogura, M | 1 |
| Seino, Y | 1 |
| Kawamori, R | 2 |
| Kume, A | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Ratner, R | 2 |
| Orchard, T | 2 |
| Costello, MF | 1 |
| Crandall, J | 2 |
| Diamanti-Kandarakis, E | 1 |
| Alexandraki, K | 1 |
| Protogerou, A | 1 |
| Piperi, C | 1 |
| Papamichael, C | 1 |
| Aessopos, A | 1 |
| Lekakis, J | 1 |
| Mavrikakis, M | 1 |
| Minoura, H | 1 |
| Takeshita, S | 1 |
| Yamamoto, T | 1 |
| Mabuchi, M | 1 |
| Hirosumi, J | 1 |
| Takakura, S | 1 |
| Kawamura, I | 1 |
| Seki, J | 1 |
| Manda, T | 1 |
| Ita, M | 1 |
| Mutoh, S | 1 |
| Yao-Borengasser, A | 3 |
| Gubern, C | 1 |
| López-Bermejo, A | 1 |
| Vendrell, J | 1 |
| Mukesh, B | 1 |
| Bhaskar, AD | 1 |
| Vijay, V | 2 |
| Maji, D | 1 |
| Roy, RU | 1 |
| Das, S | 1 |
| Schnell, O | 1 |
| Young, TK | 1 |
| Raboud, JM | 1 |
| Satyavani, K | 1 |
| Sivasankari, S | 1 |
| Van de Lisdonk, EH | 1 |
| Varma, V | 2 |
| Bodles, AM | 2 |
| Phanavanh, B | 2 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Spencer, HJ | 2 |
| McGehee, RE | 2 |
| Fried, SK | 2 |
| Florez, JC | 1 |
| Jablonski, KA | 2 |
| Franks, PW | 1 |
| Altshuler, D | 1 |
| Fujimoto, WY | 1 |
| Kriska, A | 1 |
| Hanson, R | 1 |
| Hill, JO | 1 |
| Hubbard, V | 1 |
| Stamm, E | 1 |
| Pi-Sunyer, FX | 1 |
| Eguchi, K | 1 |
| Tomizawa, H | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Numao, T | 1 |
| Fukuda, T | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| Rashidi, AA | 1 |
| Funahashi, T | 1 |
| Matsuzawa, Y | 1 |
| Edelstein, S | 1 |
| Goldstein, B | 1 |
| Fonseca, VA | 1 |
| Joshi, VV | 1 |
| Pernet, A | 1 |
| Scheen, AJ | 3 |
| Letiexhe, MR | 2 |
| Lefèbvre, PJ | 2 |
| Yoshii, H | 1 |
| Linday, LA | 1 |
| Grosskopf, I | 1 |
| Ringel, Y | 1 |
| Charach, G | 1 |
| Maharshak, N | 1 |
| Mor, R | 1 |
| Iaina, A | 1 |
| Weintraub, M | 1 |
| Li, CL | 1 |
| Pan, CY | 1 |
| Lu, JM | 1 |
| Zhu, Y | 1 |
| Wang, JH | 1 |
| Deng, XX | 1 |
| Xia, FC | 1 |
| Wang, HZ | 1 |
| Wang, HY | 1 |
| Morel, Y | 1 |
| Golay, A | 1 |
| Perneger, T | 1 |
| Lehmann, T | 1 |
| Vadas, L | 1 |
| Pasik, C | 1 |
| Reaven, GM | 1 |
| Spigset, O | 1 |
| Mjörndal, T | 1 |
| Norman, RJ | 1 |
| Kidson, WJ | 1 |
| Cuneo, RC | 1 |
| Zacharin, MR | 1 |
| Dornhorst, A | 1 |
| Lehtovirta, M | 1 |
| Forsén, B | 1 |
| Gullström, M | 1 |
| Häggblom, M | 1 |
| Eriksson, JG | 1 |
| Taskinen, MR | 1 |
| Groop, L | 1 |
| Kotler, DP | 1 |
| Kent, SC | 1 |
| Legro, RS | 1 |
| Lewy, V | 1 |
| Danadian, K | 1 |
| Saad, R | 1 |
| Vondra, K | 1 |
| Nĕmcová, D | 1 |
| Stárka, L | 1 |
| Bílek, R | 1 |
| Bendlová, B | 1 |
| Hampl, R | 1 |
| Hill, M | 1 |
| Hoza, J | 1 |
| Kot'átková, A | 1 |
| Vrbíková, J | 1 |
| Zamrazil, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Beta Cell Restoration Through Fat Mitigation[NCT01763346] | 88 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China.[NCT03441750] | Phase 4 | 1,724 participants (Actual) | Interventional | 2017-04-25 | Completed | ||
| Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19[NCT04542213] | Phase 3 | 70 participants (Actual) | Interventional | 2020-08-01 | Completed | ||
| Restoring Insulin Secretion Pediatric Medication Study[NCT01779375] | Phase 3 | 91 participants (Actual) | Interventional | 2013-06-16 | Completed | ||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)[NCT03862950] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-05-24 | Recruiting | ||
| Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity[NCT01960205] | Phase 4 | 80 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial[NCT04131582] | Phase 3 | 34 participants (Anticipated) | Interventional | 2019-09-01 | Recruiting | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| Dietary Oxysterols and β-Cell Function Among African Americans[NCT05072587] | 24 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| The Emirates Heart Health Project: A Stepped-wedge Cluster Randomized-controlled Trial of a Family-based Health Coach Guided Dietary and Exercise Intervention for Reducing Weight and Cardiovascular Risk in Overweight and Obese Adult Nationals of the Unite[NCT04688684] | 80 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | |||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study[NCT04231838] | 576 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| Effect of Acute or Chronic Ingestion of Sucralose on Serum Insulin in Young and Healthy Adults: a Randomized, Double-blind, Placebo-controlled Trial[NCT03703141] | 95 participants (Actual) | Interventional | 2016-09-27 | Completed | |||
| The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India[NCT01283308] | 599 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| Implementation of a Pragmatic Approach to Lower Diabetes Mellitus Risk After a Diagnosis of Gestational Diabetes Mellitus[NCT05280496] | Phase 3 | 36 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Face-it: A Health Promotion Intervention for Women With Prior Gestational Diabetes and Their Families - A Randomised Controlled Trial[NCT03997773] | 277 participants (Actual) | Interventional | 2019-05-21 | Active, not recruiting | |||
| Screening for Prediabetes and Early Diabetes in Primary Care[NCT00787839] | 1,939 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| A Pragmatic and Scalable Strategy Using Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK[NCT01570946] | 1,171 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Metformin Decreases Plasma Resistin Concentrations in Pediatric Patients With Impaired Glucose Tolerance: A Placebo-controlled Randomized Clinical Trial[NCT01394887] | Phase 2/Phase 3 | 52 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Group Medical Visits (GMVs) in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People[NCT02002143] | 128 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study[NCT00729079] | 36 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Helping the Poor Quit Smoking: Specialized Quitlines and Meeting Basic Needs[NCT03194958] | 1,944 participants (Actual) | Interventional | 2017-06-05 | Completed | |||
| Effect of the CAIPaDi Care Model in Relatives of Patients With Type 2 Diabetes Mellitus[NCT03234946] | 97 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | |||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Physical Activity and Sedentary Behavior Change; Impact on Lifestyle Intervention Effects for Diabetes Translation[NCT02467881] | 308 participants (Actual) | Interventional | 2015-09-30 | Active, not recruiting | |||
| A Community-based Lifestyle Intervention to Reduce the Risk of Diabetes in Qingdao, China----Qingdao Diabetes Prevention Project (2005-2012)[NCT01053195] | 276,793 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Exercise, Prediabetes and Diabetes After Renal Transplantation.[NCT04489043] | 60 participants (Anticipated) | Interventional | 2019-09-05 | Recruiting | |||
| Effects of a Community-based Weight Loss Programme Targetting Chinese Overweight Adults With Pre-diabetes: A Randomized Controlled Trial[NCT03609697] | 180 participants (Anticipated) | Interventional | 2018-08-10 | Active, not recruiting | |||
| Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes[NCT03398902] | 150 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | |||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.[NCT04148183] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2004-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HbA1C (NCT01763346)
Timeframe: 24 months
| Intervention | percent of hemoglobin (Mean) |
|---|---|
| Metformin | 5.84 |
| Gastric Banding | 5.73 |
mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity (NCT01763346)
Timeframe: 24 months
| Intervention | (nmol/L) adjusted for M/I (Geometric Mean) |
|---|---|
| Metformin | 3.01 |
| Gastric Banding | 3.19 |
fasting and 2-hour OGTT glucose levels (NCT01763346)
Timeframe: 24 months
| Intervention | mmol/l (Mean) | |
|---|---|---|
| fasting glucose | 2-hour glucose | |
| Gastric Banding | 5.85 | 9.92 |
| Metformin | 5.95 | 10.87 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 1.68 |
| Glargine Followed by Metformin | 1.68 |
| Placebo | 1.68 |
| Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 3.53 |
| Glargine Followed by Metformin | 3.38 |
| Placebo | 3.63 |
| Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| ACRPg | Steady State C-peptide | ACRPmax | |
| Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
| Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
| Metformin Alone | 1.93 | 11.7 | 13.4 |
| Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Geometric Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 3.58 | 4.32 |
| Liraglutide + Metformin | 3.73 | 4.58 |
| Metformin Alone | 3.65 | 4.61 |
| Placebo | 3.60 | 4.45 |
First phase response (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin Alone | 1.11 |
| Glargine Followed by Metformin | 1.12 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12)
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.52 |
| Glargine Followed by Metformin | 1.93 |
Clamp measure of insulin sensitivity (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.48 |
| Glargine Followed by Metformin | 1.70 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12).
| Intervention | nmol/L (Mean) | ||
|---|---|---|---|
| Steady State C-peptide | ACPRmax | ACPRg | |
| Glargine Followed by Metformin | 4.37 | 5.79 | 1.03 |
| Metformin Alone | 4.78 | 6.95 | 1.06 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779375)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 4.18 | 5.95 |
| Metformin Alone | 4.82 | 6.92 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
"Area under ROC curve (AROC) for prediction of diabetes (based on OGTT) and high-risk dysglycemia (based on OGTT, IGT with 2 hour OGTT glucose 140-199 mg/dl, and/or IFG with fasting glucose 110-125 mg/dl).~ROC curves are plots of (1-sensitivity) vs. (1-specificity) for all possible screening cutoffs, so a higher AROC indicates higher predictive accuracy. A perfect test would have an AROC of 1.00, while a test equivalent to tossing a coin (random) would have an AROC of 0.50; if confidence limits include 0.50, predictive accuracy is no better than chance.~It is important to appreciate that while AROC analysis can show the relative accuracy of different screening tests, and aid the selection of which test to use in clinical practice, such an analysis does not define what the optimal screening test cutoff is. Selection of the optimal cutoff generally requires consideration of other factors, such as costs and/or the clinical importance of having higher or lower sensitivity." (NCT00787839)
Timeframe: 3 years
| Intervention | area under ROC curve (Number) |
|---|---|
| GCTpl - Diabetes | .85 |
| GCTcap - Diabetes | .82 |
| RPG - Diabetes | .76 |
| RCG - Diabetes | .72 |
| A1c - Diabetes | .67 |
| GCTpl - Dysglycemia | .76 |
| GCTcap - Dysglycemia | .73 |
| RPG - Dysglycemia | .66 |
| RCG - Dysglycemia | .64 |
| A1c - Dysglycemia | .63 |
Cost was expressed as cost (dollars) to identify a single case, with cases defined as (i) diabetes or (ii) high-risk dysglycemia. Cost projections for screening were conducted from both Medicare and VA perspectives. All screening projections assumed follow-up testing with an OGTT if the screening test exceeded a 70% specificity cut-off. (NCT00787839)
Timeframe: 3 years
| Intervention | Dollars (Number) |
|---|---|
| GCTpl - Diabetes - VA | 100 |
| GCTcap - Diabetes - VA | 93 |
| GCTpl - Dysglycemia - VA | 42 |
| GCTcap - Dysglycemia - VA | 37 |
| GCTpl - Diabetes - Medicare | 133 |
| GCTcap - Diabetes - Medicare | 125 |
| GCTpl - Dysglycemia - Medicare | 55 |
| GCTcap - Dysglycemia - Medicare | 50 |
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Pioglitazone Group | 1.02 |
| Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
| Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
| Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
| Intervention | % Change (Mean) | |||
|---|---|---|---|---|
| % Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
| Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
| Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Report quitting smoking for at least 24 hours during intervention (NCT03194958)
Timeframe: 6 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 241 |
| Specialized Quitline | 219 |
| Standard Quitline With Basic Needs Navigator | 248 |
| Specialized Quitline With Basic Needs Navigator | 235 |
Report 7-day point prevalence abstinence measured at 3-months post-baseline (NCT03194958)
Timeframe: 3 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 97 |
| Specialized Quitline | 104 |
| Standard Quitline With Basic Needs Navigator | 80 |
| Specialized Quitline With Basic Needs Navigator | 105 |
Report 7-day point prevalence abstinence measured at 6-months post --baseline (NCT03194958)
Timeframe: 6 months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Quitline | 101 |
| Specialized Quitline | 90 |
| Standard Quitline With Basic Needs Navigator | 74 |
| Specialized Quitline With Basic Needs Navigator | 103 |
43 reviews available for metformin and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Me | 2019 |
Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2021 |
Pharmacotherapeutic options for prediabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2021 |
Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Metformin; Prediabetic State; Sodium-Glucose | 2021 |
Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance.
Topics: Acarbose; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; M | 2021 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; | 2017 |
THE PHYSIOLOGY BEHIND DIABETES MELLITUS IN PATIENTS WITH PHEOCHROMOCYTOMA: A REVIEW OF THE LITERATURE.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Blood Glucose; Catecholamines; Diabetes Mellitus; Diabetes Mel | 2017 |
Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.
Topics: Administration, Oral; Diabetes Mellitus; Diabetes, Gestational; Female; Glucose Intolerance; Humans; | 2017 |
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Topics: Acarbose; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diet; Exercise; Fasting; Glucose | 2018 |
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes | 2019 |
Adipokines in the HIV/HAART-associated lipodystrophy syndrome.
Topics: Adiponectin; Glucose Intolerance; HIV-Associated Lipodystrophy Syndrome; Humans; Leptin; Metformin; | 2013 |
[Search of new therapeutics for cerebral infarction--post-ischemic glucose intolerance induced by cerebral neuronal damage and the involvement of the communication system between the brain and peripheral tissues].
Topics: Animals; Brain; Brain Ischemia; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Intracell | 2013 |
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated | 2016 |
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemi | 2016 |
Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Fatty Acids, Nonesterified; Glucose I | 2009 |
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
Topics: Blood Glucose; Fatty Acids; Glucose Intolerance; Heart Failure; Humans; Hypoglycemic Agents; Increti | 2010 |
[Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress].
Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Brain; Brain Ischemia; Disease Models, | 2011 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female | 2012 |
Abnormal glucose metabolism: diagnosis and management in the ambulatory setting.
Topics: Ambulatory Care; Blood Glucose Self-Monitoring; Diabetes, Gestational; Diet Therapy; Exercise Therap | 2012 |
Diabetes and pancreatic cancer.
Topics: Age Factors; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Early Detection o | 2012 |
Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement.
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic A | 2002 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
[Is it possible to prevent type 2 diabetes?].
Topics: Acarbose; Adult; Aged; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Glucose Intolerance; Human | 2003 |
Is metformin more than an oral hypoglycaemic agent?
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; H | 2003 |
Do effects on blood pressure contribute to improved clinical outcomes with metformin?
Topics: Blood Pressure; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type | 2003 |
The potential of metformin for diabetes prevention.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Glycemic treatment: Control of glycemia.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; H | 2004 |
[Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Disease Progression; Exercise Therapy; Glucose Into | 2005 |
[Characteristic of metformin for treatment of impaired glucose tolerance].
Topics: Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Glucose; Glucose Intolerance; Humans; Hypog | 2005 |
[Diabetes prevention program (metformin)].
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Insu | 2005 |
[Diet therapy for impaired glucose tolerance].
Topics: Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Dietary Fiber; Energy Intake; Evidence-Based Med | 2005 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy | 2005 |
[Treatment for coronary artery disease patients with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Coronary Artery Bypass; Coronary Artery Disease; Glucose Intolerance; Glycosid | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome--a management update.
Topics: Contraceptives, Oral; Family Practice; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inf | 2005 |
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose Intolerance; | 2006 |
Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glucose Intolerance; Glucos | 2007 |
[Therapeutic approach to a multi-metabolic syndrome].
Topics: Acarbose; Combined Modality Therapy; Diet Therapy; Enzyme Inhibitors; Exercise; Glucose Intolerance; | 1995 |
Effects of metformin in obese patients with impaired glucose tolerance.
Topics: Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Ob | 1995 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
Insulin-lowering therapeutic modalities for polycystic ovary syndrome.
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretio | 1999 |
Polycystic ovary syndrome in adolescents.
Topics: Adolescent; Anovulation; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glucose Intoler | 2002 |
70 trials available for metformin and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2021 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program.
Topics: Adult; Diabetes Mellitus; Female; Glucose; Glucose Intolerance; Humans; Male; Metformin; Middle Aged | 2022 |
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled t
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; East Asian People; Female; Glucose; Glucose Into | 2023 |
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
Topics: Adolescent; Adult; Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; | 2023 |
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.
Topics: Adolescent; Adult; Aged; China; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Male | 2020 |
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Topics: Adult; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Metho | 2020 |
Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2020 |
Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glu | 2020 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intol | 2021 |
Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program.
Topics: Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Life Style; Male; Metformin; Sex Hor | 2020 |
Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
Topics: Autoantibodies; Autoantigens; Autoimmunity; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; | 2021 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase | 2017 |
Effect of Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Double-Blind Method; Female; Glucose Intoleranc | 2017 |
Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Estradiol; Female; Glucose Intolerance; Gonadal Steroid Hor | 2017 |
Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study.
Topics: Blood Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemi | 2017 |
Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fem | 2017 |
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Topics: Adolescent; Adult; Body Mass Index; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Metf | 2018 |
Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adolescent; Age Factors; Blood Glucose; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2018 |
Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastroplasty; Glucose Intolerance; Gl | 2018 |
Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation.
Topics: Adult; Diabetes Mellitus; Drug Monitoring; Female; Glucose Intolerance; Glucose Tolerance Test; Huma | 2019 |
Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.
Topics: Adult; Aged; Alaskan Natives; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Female; Follow-Up | 2019 |
Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
Topics: Adiposity; Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Dou | 2013 |
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program.
Topics: Aged; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Glucose Intolerance; Gonadal Steroid | 2013 |
Sex hormone binding globulin and sex steroids among premenopausal women in the diabetes prevention program.
Topics: Adult; Black or African American; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus; Die | 2013 |
Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibr | 2013 |
Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Topics: Age Factors; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2014 |
Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Fem | 2013 |
Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
Topics: Biomarkers; Blood Glucose; Clinical Protocols; Feasibility Studies; Glucose Intolerance; Glucose Tol | 2015 |
The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diet; Female; Follow-Up Studies; Glucose I | 2016 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Gro
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D | 2009 |
Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1).
Topics: Adult; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; | 2009 |
Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Cholesterol, HDL; Diabetes Mellitus, Type 2; Energ | 2009 |
Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; | 2009 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Fem | 2010 |
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
Topics: Adult; Alanine Transaminase; Biomarkers; Diabetes Mellitus; Fatty Liver; Female; Glucose Intolerance | 2010 |
Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Humans; Hypog | 2010 |
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Intoleran | 2010 |
Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance--analysis of the Indian Diabetes Prevention Programmes.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolera | 2012 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Fema | 2012 |
Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.
Topics: Adiponectin; Adolescent; Biomarkers; C-Reactive Protein; Child; Child, Preschool; Drug Administratio | 2012 |
Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Glucose; D | 2012 |
Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program.
Topics: Aged; Blood Glucose; Body Mass Index; Dehydroepiandrosterone; Estradiol; Ethnicity; Female; Glucose | 2012 |
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy.
Topics: Behavior Therapy; Blood Glucose; Diabetes Mellitus; Estradiol; Estrogen Replacement Therapy; Fasting | 2013 |
Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; F | 2003 |
The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.
Topics: Adult; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Double-Blind Method; Endothelium, Vascula | 2004 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury.
Topics: Adult; Burns; Calorimetry, Indirect; Double-Blind Method; Female; Glucose Intolerance; Humans; Hyper | 2005 |
Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Glucose Intolerance; Gluco | 2005 |
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypertension; Hyper | 2005 |
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypertension; Hyper | 2005 |
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypertension; Hyper | 2005 |
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypertension; Hyper | 2005 |
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.
Topics: Blood Coagulation; Blood Glucose; Body Mass Index; Diabetes Mellitus; Female; Glucose Intolerance; H | 2005 |
Metformin administration improves endothelial function in women with polycystic ovary syndrome.
Topics: Adult; Brachial Artery; Endothelin-1; Endothelium, Vascular; Female; Glucose Intolerance; Humans; Hy | 2005 |
Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein.
Topics: Adult; Antimicrobial Cationic Peptides; Blood Proteins; Diabetes Mellitus, Type 2; Gene Expression R | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Topics: Adult; Asian People; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Progression; Fema | 2006 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose I | 2005 |
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Intolerance; Huma | 2006 |
Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme.
Topics: Adult; Diabetes Mellitus; Female; Glucose Intolerance; Humans; India; Insulin Resistance; Life Style | 2007 |
Relationship of body size and shape to the development of diabetes in the diabetes prevention program.
Topics: Adult; Body Composition; Body Mass Index; Body Size; Diabetes Mellitus, Type 2; Ethnicity; Female; G | 2006 |
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
Topics: Alleles; ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Disease Progression; Female; | 2007 |
Body size and shape changes and the risk of diabetes in the diabetes prevention program.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Size; Cohort Studies; Diabetes Mellitus; Diabetes Mellitu | 2007 |
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Topics: Adiponectin; Aged; Aldosterone; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Fa | 2007 |
Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypo | 2008 |
Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Constitution; C-Peptide; Cross-Over Studies; Double-Blind Method; Female; | 1995 |
Trivalent chromium and the diabetes prevention program.
Topics: Chromans; Chromium; Clinical Protocols; Complementary Therapies; Diabetes Mellitus, Type 2; Diet; Ex | 1997 |
Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Dietary Fats; Female; Glucose Intoler | 1997 |
Effect of metformin on patients with impaired glucose tolerance.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Double-Blind Method; Female; Glucose Intolerance; Glucose T | 1999 |
Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.
Topics: Blood Glucose; C-Peptide; Double-Blind Method; Female; Fructosamine; Glucose Intolerance; Glycated H | 1999 |
Metabolic effects of metformin in patients with impaired glucose tolerance.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acid | 2001 |
84 other studies available for metformin and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance.
Topics: Animals; Diet, High-Fat; Female; Fetal Growth Retardation; Glucose Intolerance; Humans; Infectious D | 2022 |
Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments.
Topics: Animals; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome.
Topics: Animals; Gastrointestinal Microbiome; Glucose Intolerance; Metabolic Syndrome; Metformin; Rats; Rats | 2022 |
[Gestational diabetes mellitus in a hospital in the city of Buenos Aires, Argentina: incidence, treatment, and frequency of screening for reclassification after childbirth]
Topics: Argentina; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose Intolera | 2022 |
Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucose; Glucose Intoleranc | 2023 |
Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucose; Glucose Intoleranc | 2023 |
Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucose; Glucose Intoleranc | 2023 |
Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucose; Glucose Intoleranc | 2023 |
Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose Intolerance; High Fructose Corn Syrup; M | 2023 |
Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway.
Topics: Adipocytes; Animals; Diet, High-Fat; Flavonoids; Gene Expression Regulation; Gluconeogenesis; Glucos | 2019 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Elevated T-helper 2 cytokine levels in high fat diet-fed C57BL/6 mice are attenuated by short-term 6-week treatment with a combination of low-dose aspirin and metformin.
Topics: Animals; Aspirin; Cytokines; Drug Therapy, Combination; Glucose Intolerance; Male; Metformin; Mice; | 2020 |
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.
Topics: Animals; Appetite Depressants; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Gluco | 2019 |
Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis.
Topics: Animals; Cytokines; Energy Metabolism; Glucose; Glucose Intolerance; Guinea Pigs; Hypoglycemic Agent | 2020 |
Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice.
Topics: Animals; Anti-Inflammatory Agents; Chlorogenic Acid; Diet, High-Fat; Glucose Intolerance; Hypoglycem | 2021 |
Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cardiotonic Agents; Diabetes Mellitus, Experimental | 2021 |
Editorial: Understanding the Heterogeneity in Exercise-Induced Changes in Glucose Metabolism to Help Optimize Treatment Outcomes.
Topics: Blood Glucose; Exercise; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Prognosis | 2021 |
Metformin in combination with genistein ameliorates skeletal muscle inflammation in high-fat diet fed c57BL/6 mice.
Topics: Animals; Diet, High-Fat; Drug Therapy, Combination; Genistein; Glucose Intolerance; Hypolipidemic Ag | 2021 |
Metformin as targeted treatment in fragile X syndrome.
Topics: Adult; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; Fragile X Syndrome; Gluc | 2018 |
Incidence and Contributing Factors of Persistent Hyperglycemia at 6-12 Weeks Postpartum in Iranian Women with Gestational Diabetes: Results from LAGA Cohort Study.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fasting; Fem | 2017 |
Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diet, High-Fat; Dietary Supple | 2017 |
Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.
Topics: Aging; Animals; Female; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Immunosuppressive | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase.
Topics: Adenosine Monophosphate; Aminoimidazole Carboxamide; Animals; Base Sequence; Chickens; Disease Model | 2018 |
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.
Topics: Bacteroides; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Micro | 2018 |
Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance.
Topics: Animals; Biological Products; Biopsy, Needle; Carbamates; Disease Models, Animal; Glucose Intoleranc | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Update in endocrinology: evidence published in 2012.
Topics: Biliopancreatic Diversion; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2013 |
Effect of metformin on substrate utilization after exercise training in adults with impaired glucose tolerance.
Topics: Adult; Blood Glucose; Exercise; Glucose; Glucose Intolerance; Humans; Insulin; Metformin | 2013 |
Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice.
Topics: Acetyl-CoA Carboxylase; Adipokines; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Glucose | 2013 |
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.
Topics: Animals; Benzodiazepines; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Glucos | 2014 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Di | 2013 |
Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose; Glucose Intol | 2014 |
Improved metabolic response after 16 weeks of calorie-restricted low-glycaemic index diet and metformin in impaired glucose tolerance subjects.
Topics: Adult; Anthropometry; Body Composition; Caloric Restriction; Eating; Female; Glucose Intolerance; Gl | 2014 |
The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
Topics: Adult; Bromocriptine; Dopamine Agonists; Female; Glucose Intolerance; Humans; Hyperprolactinemia; Hy | 2015 |
Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement.
Topics: Animals; Blood Glucose; Carcinoma 256, Walker; Cell Proliferation; Diabetes Mellitus, Experimental; | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
(5) Prevention or delay of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exercise; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Ob | 2015 |
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Topics: Animals; Body Weight; Cell Cycle; Diet, Diabetic; Energy Intake; Glucose Intolerance; Hypoglycemic A | 2015 |
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.
Topics: Animals; Bombyx; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Drug Evaluation, | 2015 |
Effects of exercise and metformin on the prevention of glucose intolerance: a comparative study.
Topics: Animals; Blood Glucose; Dexamethasone; Fasting; Glucocorticoids; Glucose; Glucose Intolerance; Gluco | 2015 |
Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis.
Topics: Animals; Glucose Intolerance; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resi | 2016 |
Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats.
Topics: Adiposity; Animals; Central Nervous System Depressants; Circadian Rhythm; Glucose Intolerance; Hypog | 2016 |
Consensus on the Prevention of Type 2 Diabetes in Chinese Adults.
Topics: Acarbose; Blood Glucose; Consensus; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Metformi | 2017 |
Gestational diabetes: an opportunity for improvement.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Disease Progression; Female; Glucose Intolerance; Human | 2008 |
Glucose homeostasis is impaired by a paradoxical interaction between metformin and insulin in carnivorous rainbow trout.
Topics: Animal Nutritional Physiological Phenomena; Animals; Blood Glucose; Feeding Behavior; Gene Expressio | 2009 |
Many Americans have pre-diabetes and should be considered for metformin therapy.
Topics: Cross-Sectional Studies; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents | 2010 |
Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Topics: Animals; Blood Glucose; Class I Phosphatidylinositol 3-Kinases; Diabetes Mellitus; Down-Regulation; | 2010 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose I | 2010 |
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Dietary Fats; Gluc | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agen | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agen | 2010 |
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agen | 2010 |
In vitro and in vivo acute antihyperglycemic effects of five selected indigenous plants from Jordan used in traditional medicine.
Topics: Achillea; alpha-Amylases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Ethn | 2011 |
Successful strategy to improve glucose tolerance in Thai obese youth.
Topics: Adolescent; Asian People; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Diet; Ex | 2010 |
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucose Intolerance; Humans; Hy | 2011 |
What's next for diabetes prevention?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Insulin-Secreting Cel | 2011 |
Should all women with PCOS be treated for insulin resistance?
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metab | 2012 |
Highlights from the latest articles in diabetes pharmacogenomics.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2012 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; Drug Combinations; Female; Fluorobenzenes; Follow-Up Studies; | 2012 |
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic | 2012 |
What's preventing us from preventing type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Approval; Glucose Intolerance; Humans; Hypoglycemic Agents; Insuranc | 2012 |
[Glucose intolerance in myotonic dystrophy type 1].
Topics: Glucose Intolerance; Humans; Insulin Resistance; Metformin; Myotonic Dystrophy | 2012 |
Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines.
Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Databases, Factual; Drug Prescriptions; Female | 2013 |
[Physical activity in hyperglycemia and type 2 diabetes. Effective but still underutilized].
Topics: Adult; Aged; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Exercise; Female | 2003 |
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
Topics: Animals; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Eating; Glucose Intolerance; Male; Metfo | 2004 |
Impaired glucose tolerance and impaired fasting glucose.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes, Gestational; Disease Progression; Female; Glucose Intole | 2004 |
[Cost-effective analysis of preventive treatment on diabetes].
Topics: Acarbose; Attitude to Health; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Follow-Up Studies; G | 2004 |
Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Topics: Acarbose; Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Progression; Female; Glu | 2004 |
Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Topics: Adult; Aged; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; | 2005 |
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Gluc | 2005 |
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.
Topics: Abdominal Fat; Adiponectin; Adult; Blood Glucose; Female; Gene Expression; Glucose Intolerance; Gluc | 2006 |
[Glucose control in cardiac disease].
Topics: Acarbose; Blood Glucose; Controlled Clinical Trials as Topic; Diabetes Complications; Glucose; Gluco | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.
Topics: Adiponectin; Adult; Biomarkers; Diabetes Mellitus; Disease Progression; Ethnicity; Female; Glucose I | 2008 |
Treatment of impaired glucose tolerance in childhood.
Topics: Child; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Insulin Resistance; Metformin; Obesit | 2008 |
Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Type 2; Digoxin; Fata | 1999 |
Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group.
Topics: Diabetes Mellitus, Type 2; Endocrinology; Evidence-Based Medicine; Female; Glucose Intolerance; Huma | 2001 |
A comparison of glyburide and insulin in women with gestational diabetes mellitus.
Topics: Adult; Diabetes, Gestational; Female; Glucose Intolerance; Glyburide; Humans; Hypoglycemic Agents; I | 2001 |
Metabolic alterations in HIV lipodystrophy. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Topics: Acidosis; Anti-HIV Agents; Bone Diseases, Metabolic; Cost-Benefit Analysis; Glucose; Glucose Intoler | 2001 |
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
Topics: Acarbose; Adult; Aged; Diabetes Mellitus, Type 2; Diet; Disease Progression; Exercise; Female; Gluco | 2001 |
Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Body Composition; Female; Glucos | 2002 |
[Metformin has a positive effect on disorders of carbohydrate metabolism in long-term care with low doses of prednisone].
Topics: Adolescent; Adult; Female; Glucocorticoids; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyp | 2002 |